In vitro induction of fetal hemoglobin in erythroid cells derived from CD133+ cells by transforming growth factor-β and stem cell factor

Iranian Journal of Biotechnology

Volumn 6, Issue 3, 2008, Pages 157-163

  Atashi, Amir ^a   Soleimani, Masoud ^a   Kaviani, Saeid ^a   Hajifathali, Abbas ^b   Arefian, Ehsan ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Stem Cell Technology Institute   (Iran)

Author keywords

globin; CD133+ cells; Fetal hemoglobin; SCF; TGF

Indexed keywords

GAMMA GLOBIN; HEMOGLOBIN F; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BONE MARROW; CELL ISOLATION; CONTROLLED STUDY; DRUG ACTIVITY; ERYTHROID CELL; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION; GENETIC DISORDER; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA;

EID: 60549091361     PISSN: 17283043     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Atweh GF, Schechter AN (2001). Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol. 8: 123-130.
2. Bhanu NV, Trice TA, Lee YT, Gantt NM, Oneal P, Schwartz JD, Noel P, Miller JL (2005). A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells. Blood 105: 387-393.
3. Bohmer RM (2003). Reactivation of fetal hemoglobin in adult stem cell erythropoiesis by transforming growth factor-beta. J Hematoth Stem Cell Res. 12: 499-504.
4. Bohmer RM, Campbell TA, Bianchi DW (2000). Selectively increased growth of fetal hemoglobin-expressing adult erythroid progenitors after brief treatment of early progenitors with transforming growth factor beta. Blood 95: 2967-2974.
5. Cao H, Jung M, Stamatoyannopoulos G (2005). Hydroxamide derivatives of short-chain fatty acid have erytbropoietic activity and induce gamma gene expression in vivo. Exp Hematol. 33: 1443-1449.
6. Cao H, Stamatoyannopoulos G (2006). Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin. Am J Hematol. 81:981-983.
7. Coleman E, Inusa B (2007). Sickle cell anemia: targeting the role of fetal hemoglobin in therapy. Clin Pediatr. 46: 386-91.
8. DeSimone J, Koshy M, Dora L, Lavelle D, Bressler L, Molokie R, Talischy N (2002). Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99: 3905-3908.
9. Fathallah H, Atweh GF (2006). Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematol Am Soc Hematol Educ Program. 58-62.
10. Gabbianelli M, Morsilli O, Massa A, Pasquini L, Cianciulli P, Testa U, Peschle C (2008). Effective erythropoiesis and HbF reactivation induced by kit ligand in beta-thalassemia. Blood 111: 421-429.
11. Gabbianelli M, Testa U, Massa A, Morsilli O, Saulle E, Sposi NM, Petrucci E, Mariani G, Peschle C (2003). HbF reactivation in sibling BFU-E colonies: synergistic interaction of kit ligand with low-dose dexamethasone. Blood 101: 2826-2832.
12. Gambari R, Fibach E (2007). Medicinal chemistry of fetal hemoglobin inducers for treatment of beta-thalassemia. Curr Med Chem. 14: 199-212.
13. Jaatinen T, Hemmoranta H, Hautaniemi S, Niemi J, Nicorici D, Laine J, Yli-Harja O, Partanen J (2006). Global gene expression profile of human cord blood-derived CD133+ cells. Stem Cells 24: 631-641.
14. Khayat AS, Antunes LM, Guimarães AC, Bahia MO, Lemos JA, Cabral IR, Lima PD, Amorim MI, Cardoso PC, Smith MA, Santos RA, Burbano RR (2006). Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea. Clin Exp Med. 6: 33-37.
15. Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB (2008). Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 148: 939-55.
16. Manca L, Masala B (2008). Disorders of the synthesis of human fetal hemoglobin. IUBMB Life 60: 94-111.
17. Mentzer WC, Kan YW (2001). Prospects for research in hematologic disorders: sickle cell disease and thalassemia. JAMA. 285: 640-642.
18. Patrinos GP, Grosveld FG (2008). Pharmacogenomics and therapeutics of hemoglobinopathies. Hemoglobin 32: 229-236.
19. Perrine SP (2008). Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. Pediatr Ann. 37: 339-346.
20. Steinberg MH, Brugnara C (2003). Pathophysiological-based approaches to treatment of sickle cell disease. Annu Rev Med. 54: 89-112.
21. Witt O, Monkemeyer S, Kanbach K, Pekrun A (2002). Induction of fetal hemoglobin synthesis by valproate: modulation of MAP kinase pathways. Am J Hematol. 71: 45-46.
22. Wojda U, Leigh KR, Njoroge JM, Jackson KA, Natarajan B, Stitely M, Miller JL (2003). Blood 101: 492-497.